Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does it matter how remission is achieved in acute leukemia?

J F Bishop1

  • 1Sydney Cancer Centre, University of Sydney, New South Wales, Australia.

Leukemia
|April 1, 1996
PubMed
Summary

High-dose cytarabine (ara-C) therapy shows promise in overcoming acute myeloid leukemia (AML) resistance and improving patient survival. This approach is tolerable as initial induction therapy for de novo AML.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chinese Doctors and Medical Treatment.

Buffalo medical journal·2023
Same author

Intensified Induction and Post-Remission Therapy for Acute Myeloid Leukaemia.

Hematology (Amsterdam, Netherlands)·2016
Same author

Phase II study of acivicin in patients with recurrent high grade astrocytoma.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2008
Same author

Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2003
Same author

Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography.

Journal of chromatography. B, Biomedical sciences and applications·2002
Same author

Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia.

British journal of haematology·2001

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Acute myeloid leukemia (AML) treatment failure stems from drug resistance and bone marrow failure complications.
  • Cytarabine (ara-C) is a key antileukemic drug, but resistance limits its efficacy.
  • The Australian Leukemia Study Group (ALSG) explores improved leukemia control strategies.

Purpose of the Study:

  • To investigate the efficacy and tolerability of high-dose cytarabine (HIDAC) in initial induction therapy for de novo AML.
  • To determine the optimal timing for treatment intensification in AML management.

Main Methods:

  • Analysis of data from the Australian Leukemia Study Group (ALSG) clinical trials.
  • Evaluation of high-dose cytarabine (HIDAC) as an induction and salvage regimen.
  • Assessment of dose-effect relationships for cytarabine (ara-C) in AML.

Main Results:

  • High-dose cytarabine (HIDAC) demonstrates potential to overcome ara-C resistance in leukemic blasts.
  • Evidence suggests a dose-effect relationship for ara-C in AML treatment.
  • HIDAC use is associated with prolonged remission duration and disease-free survival.
  • HIDAC is tolerable as initial induction therapy in de novo AML patients.

Conclusions:

  • High-dose cytarabine (HIDAC) is a viable and tolerable option for initial induction therapy in de novo AML.
  • Further research is needed to determine the optimal timing for intensifying AML treatment strategies.

Related Experiment Videos